Date:
Location: Four Seasons,
Date:
Location:
Leerink Partners Biopharma Summit
Date:
Location: Rosewood Miramar Beach,
Date:
Location:
Links to the presentations will be posted on the Investors section of the
About
Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.
Contacts:
Danielle Spangler
Investor Relations
dspangler@reneopharma.com
Media Inquiries
matthew.purcell@russopartnersllc.com
Source:
2023 GlobeNewswire, Inc., source